24 results on '"Eisen, Tim"'
Number of results to display per page
Search Results
2. A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)
- Author
-
Stewart, Grant D., Welsh, Sarah J., Ursprung, Stephan, Gallagher, Ferdia A., Jones, James O., Shields, Jacqui, Smith, Christopher G., Mitchell, Thomas J., Warren, Anne Y., Bex, Axel, Boleti, Ekaterini, Carruthers, Jade, Eisen, Tim, Fife, Kate, Hamid, Abdel, Laird, Alexander, Leung, Steve, Malik, Jahangeer, Mendichovszky, Iosif A., Mumtaz, Faiz, Oades, Grenville, Priest, Andrew N., Riddick, Antony C. P., Venugopal, Balaji, Welsh, Michelle, Riddle, Kathleen, Hopcroft, Lisa E. M., and Jones, Robert J.
- Published
- 2022
- Full Text
- View/download PDF
3. Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT.
- Author
-
Collinson, Fiona, Royle, Kara-Louise, Swain, Jayne, Ralph, Christy, Maraveyas, Anthony, Eisen, Tim, Nathan, Paul, Jones, Robert, Meads, David, Wah, Tze Min, Martin, Adam, Bestall, Janine, Kelly-Morland, Christian, Linsley, Christopher, Oughton, Jamie, Chan, Kevin, Theodoulou, Elisavet, Arias-Pinilla, Gustavo, Kwan, Amy, and Daverede, Luis
- Published
- 2024
- Full Text
- View/download PDF
4. Data from The UK Lung Screen (UKLS): Demographic Profile of First 88,897 Approaches Provides Recommendations for Population Screening
- Author
-
McRonald, Fiona E., primary, Yadegarfar, Ghasem, primary, Baldwin, David R., primary, Devaraj, Anand, primary, Brain, Kate E., primary, Eisen, Tim, primary, Holemans, John A., primary, Ledson, Martin, primary, Screaton, Nicholas, primary, Rintoul, Robert C., primary, Hands, Christopher J., primary, Lifford, Kate, primary, Whynes, David, primary, Kerr, Keith M., primary, Page, Richard, primary, Parmar, Mahesh, primary, Wald, Nicholas, primary, Weller, David, primary, Williamson, Paula R., primary, Myles, Jonathan, primary, Hansell, David M., primary, Duffy, Stephen W., primary, and Field, John K., primary
- Published
- 2023
- Full Text
- View/download PDF
5. Supplementary Figures 1 - 2, Tables 1 - 3 from The UK Lung Screen (UKLS): Demographic Profile of First 88,897 Approaches Provides Recommendations for Population Screening
- Author
-
McRonald, Fiona E., primary, Yadegarfar, Ghasem, primary, Baldwin, David R., primary, Devaraj, Anand, primary, Brain, Kate E., primary, Eisen, Tim, primary, Holemans, John A., primary, Ledson, Martin, primary, Screaton, Nicholas, primary, Rintoul, Robert C., primary, Hands, Christopher J., primary, Lifford, Kate, primary, Whynes, David, primary, Kerr, Keith M., primary, Page, Richard, primary, Parmar, Mahesh, primary, Wald, Nicholas, primary, Weller, David, primary, Williamson, Paula R., primary, Myles, Jonathan, primary, Hansell, David M., primary, Duffy, Stephen W., primary, and Field, John K., primary
- Published
- 2023
- Full Text
- View/download PDF
6. Data from Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
- Author
-
Manola, Judith, primary, Royston, Patrick, primary, Elson, Paul, primary, McCormack, Jennifer Bacik, primary, Mazumdar, Madhu, primary, Négrier, Sylvie, primary, Escudier, Bernard, primary, Eisen, Tim, primary, Dutcher, Janice, primary, Atkins, Michael, primary, Heng, Daniel Y.C., primary, Choueiri, Toni K., primary, Motzer, Robert, primary, and Bukowski, Ronald, primary
- Published
- 2023
- Full Text
- View/download PDF
7. supplementary data from A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma
- Author
-
Liu, Xiaoyan, primary, Swen, Jesse J., primary, Diekstra, Meta H.M., primary, Boven, Epie, primary, Castellano, Daniel, primary, Gelderblom, Hans, primary, Mathijssen, Ron H.J., primary, Vermeulen, Sita H., primary, Oosterwijk, Egbert, primary, Junker, Kerstin, primary, Roessler, Max, primary, Alexiusdottir, Kristin, primary, Sverrisdottir, Asgerdur, primary, Radu, Marius T., primary, Ambert, Valentin, primary, Eisen, Tim, primary, Warren, Anne, primary, Rodríguez-Antona, Cristina, primary, García-Donas, Jesus, primary, Böhringer, Stefan, primary, Koudijs, Karel K.M., primary, Kiemeney, Lambertus A.L.M., primary, Rini, Brian I., primary, and Guchelaar, Henk-Jan, primary
- Published
- 2023
- Full Text
- View/download PDF
8. Supplementary Figure 1 from Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
- Author
-
Manola, Judith, primary, Royston, Patrick, primary, Elson, Paul, primary, McCormack, Jennifer Bacik, primary, Mazumdar, Madhu, primary, Négrier, Sylvie, primary, Escudier, Bernard, primary, Eisen, Tim, primary, Dutcher, Janice, primary, Atkins, Michael, primary, Heng, Daniel Y.C., primary, Choueiri, Toni K., primary, Motzer, Robert, primary, and Bukowski, Ronald, primary
- Published
- 2023
- Full Text
- View/download PDF
9. Supplementary Tables and Figures from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma
- Author
-
Armstrong, Andrew J., primary, Nixon, Andrew B., primary, Carmack, Andrea, primary, Yang, Qian, primary, Eisen, Tim, primary, Stadler, Walter M., primary, Jones, Robert J., primary, Garcia, Jorge A., primary, Vaishampayan, Ulka N., primary, Picus, Joel, primary, Hawkins, Robert E., primary, Hainsworth, John D., primary, Kollmannsberger, Christian K., primary, Logan, Theodore F., primary, Puzanov, Igor, primary, Pickering, Lisa M., primary, Ryan, Christopher W., primary, Protheroe, Andrew, primary, George, Daniel J., primary, and Halabi, Susan, primary
- Published
- 2023
- Full Text
- View/download PDF
10. Supplementary Figure 2 from Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
- Author
-
Manola, Judith, primary, Royston, Patrick, primary, Elson, Paul, primary, McCormack, Jennifer Bacik, primary, Mazumdar, Madhu, primary, Négrier, Sylvie, primary, Escudier, Bernard, primary, Eisen, Tim, primary, Dutcher, Janice, primary, Atkins, Michael, primary, Heng, Daniel Y.C., primary, Choueiri, Toni K., primary, Motzer, Robert, primary, and Bukowski, Ronald, primary
- Published
- 2023
- Full Text
- View/download PDF
11. Supplementary Figure 4a from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma
- Author
-
Armstrong, Andrew J., primary, Nixon, Andrew B., primary, Carmack, Andrea, primary, Yang, Qian, primary, Eisen, Tim, primary, Stadler, Walter M., primary, Jones, Robert J., primary, Garcia, Jorge A., primary, Vaishampayan, Ulka N., primary, Picus, Joel, primary, Hawkins, Robert E., primary, Hainsworth, John D., primary, Kollmannsberger, Christian K., primary, Logan, Theodore F., primary, Puzanov, Igor, primary, Pickering, Lisa M., primary, Ryan, Christopher W., primary, Protheroe, Andrew, primary, George, Daniel J., primary, and Halabi, Susan, primary
- Published
- 2023
- Full Text
- View/download PDF
12. Supplementary Tables 1-7 from Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
- Author
-
Manola, Judith, primary, Royston, Patrick, primary, Elson, Paul, primary, McCormack, Jennifer Bacik, primary, Mazumdar, Madhu, primary, Négrier, Sylvie, primary, Escudier, Bernard, primary, Eisen, Tim, primary, Dutcher, Janice, primary, Atkins, Michael, primary, Heng, Daniel Y.C., primary, Choueiri, Toni K., primary, Motzer, Robert, primary, and Bukowski, Ronald, primary
- Published
- 2023
- Full Text
- View/download PDF
13. Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib
- Author
-
Diekstra, Meta HM, Swen, Jesse J, Van Der Zanden, Loes FM, Vermeulen, Sita H, Boven, Epie, Mathijssen, Ron HJ, Fukunaga, Koya, Mushiroda, Taisei, Hongo, Fumiya, Oosterwijk, Egbert, Cambon-Thomsen, Anne, Castellano, Daniel, Fritsch, Achim, Donas, Jesus Garcia, Rodriguez-Antona, Cristina, Ruijtenbeek, Rob, Radu, Marius T, Eisen, Tim, Junker, Kerstin, Roessler, Max, Jaehde, Ulrich, Miki, Tsuneharu, Böhringer, Stefan, Kubo, Michiaki, Kiemeney, Lambertus ALM, Guchelaar, Henk-Jan, Medical Oncology, Internal medicine, Diekstra, Meta HM [0000-0002-9368-3650], Swen, Jesse J [0000-0002-3965-5552], van der Zanden, Loes FM [0000-0003-3914-7491], Mathijssen, Ron HJ [0000-0001-5667-5697], Cambon-Thomsen, Anne [0000-0001-8793-3644], Eisen, Tim [0000-0001-9663-4873], Guchelaar, Henk-Jan [0000-0002-7085-1383], and Apollo - University of Cambridge Repository
- Subjects
Cancer Research ,sunitinib ,clear cell renal cell carcinoma ,urologic and male genital diseases ,metastatic renal cell carcinoma ,genome wide association study ,pharmacogenetics ,single nucleotide polymorphism ,Oncology ,SDG 3 - Good Health and Well-being ,Urological cancers Radboud Institute for Health Sciences [Radboudumc 15] ,Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15] ,Renal disorders Radboud Institute for Health Sciences [Radboudumc 11] - Abstract
Contains fulltext : 251723.pdf (Publisher’s version ) (Open Access) Individual response to sunitinib in metastatic renal cell carcinoma (mRCC) patients is highly variable. Earlier, sunitinib outcome was related to single nucleotide polymorphisms (SNPs) in CYP3A5 and ABCB1. Our aim is to provide novel insights into biological mechanisms underlying sunitinib action. We included mRCC patients from the European EuroTARGET consortium (n = 550) and the RIKEN cohort in Japan (n = 204) which were analysed separately and in a meta-analysis of genome-wide association studies (GWAS). SNPs were tested for association with progression-free survival (PFS) and overall survival (OS) using Cox regression. Summary statistics were combined using a fixed effect meta-analysis. SNP rs28520013 in PDLIM3 and the correlated SNPs rs2205096 and rs111356738 both in DSCAM, showed genome-wide significance (p < 5 × 10(-8)) with PFS and OS in the meta-analysis. The variant T-allele of rs28520013 associated with an inferior PFS of 5.1 months compared to 12.5 months in non-carriers (p = 4.02 × 10(-10), HR = 7.26). T-allele carriers of rs28520013 showed an inferior OS of 6.9 months versus 30.2 months in non-carriers (p = 1.62 × 10(-8), HR = 5.96). In this GWAS we identified novel genetic variants in PDLIM3 and DSCAM that impact PFS and OS in mRCC patients receiving sunitinib. The underlying link between the identified genes and the molecular mechanisms of sunitinib action needs to be elucidated.
- Published
- 2022
- Full Text
- View/download PDF
14. Logical Imputation to Optimize Prognostic Risk Classification in Metastatic Renal Cell Cancer
- Author
-
Maurits, Jake S.F., primary, van der Zanden, Loes F.M., additional, Diekstra, Meta H.M., additional, Ambert, Valentin, additional, Castellano, Daniel, additional, Garcia-Donas, Jesus, additional, Troyas, Rosa Guarch, additional, Guchelaar, Henk-Jan, additional, Jaehde, Ulrich, additional, Junker, Kerstin, additional, Martinez-Cardus, Anna, additional, Radu, Marius T., additional, Rodriguez-Antona, Cristina, additional, Roessler, Max, additional, Warren, Anne, additional, Eisen, Tim, additional, Oosterwijk, Egbert, additional, Kiemeney, Lambertus A.L.M., additional, and Vermeulen, Sita H., additional
- Published
- 2022
- Full Text
- View/download PDF
15. Neoadjuvant and Adjuvant Therapy for Renal Cell Carcinoma
- Author
-
Haas, Naomi B., primary, Shevach, Jeffrey, additional, Davis, Ian D., additional, Eisen, Tim, additional, Gross-Gupil, Marine, additional, Kapoor, Anil, additional, Master, Viraj A., additional, Ryan, Christopher W., additional, and Schimdinger, Manuela, additional
- Published
- 2022
- Full Text
- View/download PDF
16. Hyperpolarized 13C-Pyruvate Metabolism as a Surrogate for Tumor Grade and Poor Outcome in Renal Cell Carcinoma-A Proof of Principle Study
- Author
-
Ursprung, Stephan, Woitek, Ramona, McLean, Mary, Priest, Andrew N, Crispin-Ortuzar, Mireia, Brodie, Cara R, Gill, Andrew, Gehrung, Marcel, Beer, Lucian, Riddick, Antony CP, Field-Rayner, Johanna, Grist, James T, Deen, Surrin S, Riemer, Frank, Kaggie, Joshua, Zaccagna, Fulvio, Duarte, Joao AG, Locke, Matthew J, Frary, Amy, Aho, Tevita F, Armitage, James N, Casey, Ruth, Mendichovszky, Iosif A, Welsh, Sarah, Barrett, Tristan, Graves, Martin, Eisen, Tim, Mitchell, Thomas J, Warren, Anne, Brindle, Kevin, Sala, Evis, Stewart, Grant, Gallagher, Ferdia, Ursprung, Stephan [0000-0003-2476-178X], McLean, Mary [0000-0002-3752-0179], Priest, Andrew N [0000-0002-9771-4290], Gill, Andrew [0000-0002-9287-9563], Beer, Lucian [0000-0003-4388-7580], Deen, Surrin S [0000-0002-6206-7337], Riemer, Frank [0000-0002-3805-5221], Kaggie, Joshua [0000-0001-6706-3442], Zaccagna, Fulvio [0000-0001-6838-9532], Frary, Amy [0000-0002-4373-3517], Welsh, Sarah [0000-0001-5690-2677], Barrett, Tristan [0000-0002-1180-1474], Graves, Martin [0000-0003-4327-3052], Eisen, Tim [0000-0001-9663-4873], Warren, Anne [0000-0002-1170-7867], Brindle, Kevin [0000-0003-3883-6287], Sala, Evis [0000-0002-5518-9360], Stewart, Grant [0000-0003-3188-9140], Gallagher, Ferdia [0000-0003-4784-5230], Apollo - University of Cambridge Repository, Ursprung S., Woitek R., McLean M.A., Priest A.N., Crispin-Ortuzar M., Brodie C.R., Gill A.B., Gehrung M., Beer L., Riddick A.C.P., Field-Rayner J., Grist J.T., Deen S.S., Riemer F., Kaggie J.D., Zaccagna F., Duarte J.A.G., Locke M.J., Frary A., Aho T.F., Armitage J.N., Casey R., Mendichovszky I.A., Welsh S.J., Barrett T., Graves M.J., Eisen T., Mitchell T.J., Warren A.Y., Brindle K.M., Sala E., Stewart G.D., Gallagher F.A., Gill, Andrew B [0000-0002-9287-9563], Kaggie, Joshua D [0000-0001-6706-3442], Welsh, Sarah J [0000-0001-5690-2677], Brindle, Kevin M [0000-0003-3883-6287], Stewart, Grant D [0000-0003-3188-9140], and Gallagher, Ferdia A [0000-0003-4784-5230]
- Subjects
Cancer Research ,renal cell carcinoma ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,cancer metabolism ,monocarboxylate transporter ,Article ,Hyperpolarized ,hyperpolarized 13C magnetic resonance imaging ,Oncology ,C magnetic resonance imaging ,RC254-282 - Abstract
Simple Summary We evaluated renal cancer with varying aggressive appearances on histology, using an emerging form of non-invasive metabolic MRI. This imaging technique assesses the uptake and metabolism of a breakdown product of glucose (pyruvate) labelled with hyperpolarized carbon-13. We show that pyruvate metabolism is dependent on the aggressiveness of an individual tumor and we provide a mechanism for this finding from tissue analysis of molecules influencing pyruvate metabolism, suggesting a role for its membrane transporter. Abstract Differentiating aggressive clear cell renal cell carcinoma (ccRCC) from indolent lesions is challenging using conventional imaging. This work prospectively compared the metabolic imaging phenotype of renal tumors using carbon-13 MRI following injection of hyperpolarized [1-13C]pyruvate (HP-13C-MRI) and validated these findings with histopathology. Nine patients with treatment-naïve renal tumors (6 ccRCCs, 1 liposarcoma, 1 pheochromocytoma, 1 oncocytoma) underwent pre-operative HP-13C-MRI and conventional proton (1H) MRI. Multi-regional tissue samples were collected using patient-specific 3D-printed tumor molds for spatial registration between imaging and molecular analysis. The apparent exchange rate constant (kPL) between 13C-pyruvate and 13C-lactate was calculated. Immunohistochemistry for the pyruvate transporter (MCT1) from 44 multi-regional samples, as well as associations between MCT1 expression and outcome in the TCGA-KIRC dataset, were investigated. Increasing kPL in ccRCC was correlated with increasing overall tumor grade (ρ = 0.92, p = 0.009) and MCT1 expression (r = 0.89, p = 0.016), with similar results acquired from the multi-regional analysis. Conventional 1H-MRI parameters did not discriminate tumor grades. The correlation between MCT1 and ccRCC grade was confirmed within a TCGA dataset (p < 0.001), where MCT1 expression was a predictor of overall and disease-free survival. In conclusion, metabolic imaging using HP-13C-MRI differentiates tumor aggressiveness in ccRCC and correlates with the expression of MCT1, a predictor of survival. HP-13C-MRI may non-invasively characterize metabolic phenotypes within renal cancer.
- Published
- 2022
17. External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer
- Author
-
Oza, Bhavna, primary, Eisen, Tim, additional, Frangou, Eleni, additional, Stewart, Grant D., additional, Bex, Axel, additional, Ritchie, Alastair W.S., additional, Kaplan, Rick, additional, Smith, Benjamin, additional, Davis, Ian D., additional, Stockler, Martin R., additional, Albiges, Laurence, additional, Escudier, Bernard, additional, Larkin, James, additional, Joniau, Steven, additional, Hancock, Barry, additional, Hermann, Gregers G., additional, Bellmunt, Joaquim, additional, Parmar, Mahesh K.B., additional, Royston, Patrick, additional, and Meade, Angela, additional
- Published
- 2022
- Full Text
- View/download PDF
18. Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib
- Author
-
Diekstra, Meta H.M., Swen, Jesse J., van der Zanden, Loes F.M., Vermeulen, Sita H., Boven, Epie, Mathijssen, Ron H.J., Fukunaga, Koya, Mushiroda, Taisei, Hongo, Fumiya, Oosterwijk, Egbert, Cambon-Thomsen, Anne, Castellano, Daniel, Fritsch, Achim, Donas, Jesus Garcia, Rodriguez-Antona, Cristina, Ruijtenbeek, Rob, Radu, Marius T., Eisen, Tim, Junker, Kerstin, Roessler, Max, Jaehde, Ulrich, Miki, Tsuneharu, Böhringer, Stefan, Kubo, Michiaki, Kiemeney, Lambertus A.L.M., Guchelaar, Henk Jan, Diekstra, Meta H.M., Swen, Jesse J., van der Zanden, Loes F.M., Vermeulen, Sita H., Boven, Epie, Mathijssen, Ron H.J., Fukunaga, Koya, Mushiroda, Taisei, Hongo, Fumiya, Oosterwijk, Egbert, Cambon-Thomsen, Anne, Castellano, Daniel, Fritsch, Achim, Donas, Jesus Garcia, Rodriguez-Antona, Cristina, Ruijtenbeek, Rob, Radu, Marius T., Eisen, Tim, Junker, Kerstin, Roessler, Max, Jaehde, Ulrich, Miki, Tsuneharu, Böhringer, Stefan, Kubo, Michiaki, Kiemeney, Lambertus A.L.M., and Guchelaar, Henk Jan
- Abstract
Individual response to sunitinib in metastatic renal cell carcinoma (mRCC) patients is highly variable. Earlier, sunitinib outcome was related to single nucleotide polymorphisms (SNPs) in CYP3A5 and ABCB1. Our aim is to provide novel insights into biological mechanisms underlying sunitinib action. We included mRCC patients from the European EuroTARGET consortium (n = 550) and the RIKEN cohort in Japan (n = 204) which were analysed separately and in a meta-analysis of genome-wide association studies (GWAS). SNPs were tested for association with progression-free survival (PFS) and overall survival (OS) using Cox regression. Summary statistics were combined using a fixed effect meta-analysis. SNP rs28520013 in PDLIM3 and the correlated SNPs rs2205096 and rs111356738 both in DSCAM, showed genome-wide significance (p < 5 × 10−8 ) with PFS and OS in the meta-analysis. The variant T-allele of rs28520013 associated with an inferior PFS of 5.1 months compared to 12.5 months in non-carriers (p = 4.02 × 10−10, HR = 7.26). T-allele carriers of rs28520013 showed an inferior OS of 6.9 months versus 30.2 months in non-carriers (p = 1.62 × 10−8, HR = 5.96). In this GWAS we identified novel genetic variants in PDLIM3 and DSCAM that impact PFS and OS in mRCC patients receiving sunitinib. The underlying link between the identified genes and the molecular mechanisms of sunitinib action needs to be elucidated.
- Published
- 2022
19. Hyperpolarized 13C-Pyruvate Metabolism as a Surrogate for Tumor Grade and Poor Outcome in Renal Cell Carcinoma—A Proof of Principle Study
- Author
-
Ursprung, Stephan, primary, Woitek, Ramona, additional, McLean, Mary A., additional, Priest, Andrew N., additional, Crispin-Ortuzar, Mireia, additional, Brodie, Cara R., additional, Gill, Andrew B., additional, Gehrung, Marcel, additional, Beer, Lucian, additional, Riddick, Antony C. P., additional, Field-Rayner, Johanna, additional, Grist, James T., additional, Deen, Surrin S., additional, Riemer, Frank, additional, Kaggie, Joshua D., additional, Zaccagna, Fulvio, additional, Duarte, Joao A. G., additional, Locke, Matthew J., additional, Frary, Amy, additional, Aho, Tevita F., additional, Armitage, James N., additional, Casey, Ruth, additional, Mendichovszky, Iosif A., additional, Welsh, Sarah J., additional, Barrett, Tristan, additional, Graves, Martin J., additional, Eisen, Tim, additional, Mitchell, Thomas J., additional, Warren, Anne Y., additional, Brindle, Kevin M., additional, Sala, Evis, additional, Stewart, Grant D., additional, and Gallagher, Ferdia A., additional
- Published
- 2022
- Full Text
- View/download PDF
20. Reply to U. Capitanio et al.
- Author
-
Oza, Bhavna, Eisen, Tim, Stewart, Grant D., Bex, Axel, Royston, Patrick, and Meade, Angela
- Published
- 2023
- Full Text
- View/download PDF
21. External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer
- Author
-
Bhavna Oza, Tim Eisen, Eleni Frangou, Grant D. Stewart, Axel Bex, Alastair W.S. Ritchie, Rick Kaplan, Benjamin Smith, Ian D. Davis, Martin R. Stockler, Laurence Albiges, Bernard Escudier, James Larkin, Steven Joniau, Barry Hancock, Gregers G. Hermann, Joaquim Bellmunt, Mahesh K.B. Parmar, Patrick Royston, Angela Meade, Oza, Bhavna [0000-0003-3860-1349], Eisen, Tim [0000-0001-9663-4873], Frangou, Eleni [0000-0002-5978-292X], Stewart, Grant D [0000-0003-3188-9140], Bex, Axel [0000-0002-8499-2662], Kaplan, Rick [0000-0002-0189-8348], Smith, Benjamin [0000-0002-7079-4956], Davis, Ian D [0000-0002-9066-8244], Stockler, Martin R [0000-0003-3793-8724], Albiges, Laurence [0000-0002-5734-3480], Larkin, James [0000-0001-5569-9523], Joniau, Steven [0000-0003-3195-9890], Hermann, Gregers G [0000-0002-8413-5919], Bellmunt, Joaquim [0000-0003-2328-3421], Parmar, Mahesh KB [0000-0003-0166-1700], Meade, Angela [0000-0001-6424-0554], and Apollo - University of Cambridge Repository
- Subjects
Cancer Research ,Oncology ,Recurrence ,Humans ,Sorafenib ,urologic and male genital diseases ,Prognosis ,Carcinoma, Renal Cell ,Nephrectomy ,Kidney Neoplasms - Abstract
PURPOSE The 2003 Leibovich score guides prognostication and selection to adjuvant clinical trials for patients with locally advanced renal cell carcinoma (RCC) after nephrectomy. We provide a robust external validation of the 2003 Leibovich score using contemporary data from SORCE, an international, randomized trial of sorafenib after excision of primary RCC. METHODS Data used to derive the 2003 Leibovich score were compared with contemporary data from SORCE. Discrimination and calibration of the metastasis-free survival outcome were assessed in data from patients with clear-cell RCC, using Cox proportional hazards regression, Kaplan-Meier curves, and calculation of Harrell's c indexes. Secondary analyses involved three important SORCE groups: patients with any non–clear-cell subtype, papillary, and chromophobe carcinomas. RESULTS Four hundred seven recurrences occurred in 982 patients in the Leibovich cohort and 520 recurrences were recorded in 1,445 patients in the primary SORCE cohort. Clear discrimination between intermediate-risk and high-risk SORCE cohorts was shown; hazard ratio 2.74 (95% CI, 2.29 to 3.28), c-index 0.63 (95% CI, 0.61 to 0.65). A hazard ratio of 0.61 (95% CI, 0.53 to 0.70) confirmed poor calibration of the two cohorts. Discrimination was observed in secondary populations, with c-indexes of 0.64 (95% CI, 0.59 to 0.69) for non–clear-cell RCC, 0.63 (95% CI, 0.56 to 0.69) for papillary RCC, and 0.65 (95% CI, 0.55 to 0.76) for chromophobe RCC. CONCLUSION The 2003 Leibovich score discriminates between intermediate-risk and high-risk clear-cell and non–clear-cell RCC groups in contemporary data, supporting its use for risk stratification in adjuvant clinical trials. Over time, metastasis-free survival for patients with locally advanced RCC has improved. Contemporary data from adjuvant RCC trials should be used to improve prognostication for patients with RCC.
- Published
- 2022
22. Multiparametric MRI for assessment of early response to neoadjuvant sunitinib in renal cell carcinoma
- Author
-
Ferdia A. Gallagher, Wendi Qian, Fulvio Zaccagna, Stephan Ursprung, Grant D. Stewart, Anne Y. Warren, Sarah J. Welsh, Tristan Barrett, Timothy Eisen, Andrew N. Priest, Andrea Machin, Ursprung, Stephan [0000-0003-2476-178X], Priest, Andrew N. [0000-0002-9771-4290], Warren, Anne Y. [0000-0002-1170-7867], Apollo - University of Cambridge Repository, Priest, Andrew N [0000-0002-9771-4290], Stewart, Grant [0000-0003-3188-9140], Warren, Anne [0000-0002-1170-7867], Eisen, Tim [0000-0001-9663-4873], Welsh, Sarah [0000-0001-5690-2677], Gallagher, Ferdia [0000-0003-4784-5230], Barrett, Tristan [0000-0002-1180-1474], Ursprung S., Priest A.N., Zaccagna F., Qian W., Machin A., Stewart G.D., Warren A.Y., Eisen T., Welsh S.J., Gallagher F.A., Barrett T., and Warren, Anne Y [0000-0002-1170-7867]
- Subjects
Male ,medicine.medical_treatment ,Cancer Treatment ,urologic and male genital diseases ,Nephrectomy ,Metastasis ,Diagnostic Radiology ,Renal cell carcinoma ,Basic Cancer Research ,Medicine and Health Sciences ,Sunitinib ,ComputingMilieux_MISCELLANEOUS ,Brain Mapping ,Multidisciplinary ,medicine.diagnostic_test ,Radiology and Imaging ,Middle Aged ,Magnetic Resonance Imaging ,Kidney Neoplasms ,Neoadjuvant Therapy ,Treatment Outcome ,Oncology ,Nephrology ,Renal Cancer ,Medicine ,Female ,Perfusion ,medicine.drug ,MRI ,Research Article ,medicine.medical_specialty ,Imaging Techniques ,Brain Morphometry ,Science ,Urology ,Surgical and Invasive Medical Procedures ,Neuroimaging ,Antineoplastic Agents ,Research and Analysis Methods ,Urinary System Procedures ,Diagnostic Medicine ,medicine ,Humans ,Multiparametric Magnetic Resonance Imaging ,Carcinoma, Renal Cell ,Aged ,Surgical Excision ,business.industry ,Diffusion Weighted Imaging ,Carcinoma ,Renal Cell Carcinoma ,Cancer ,Cancers and Neoplasms ,Biology and Life Sciences ,Magnetic resonance imaging ,medicine.disease ,Clinical trial ,Genitourinary Tract Tumors ,business ,Neuroscience - Abstract
Funder: NIHR Cambridge Biomedical Research Centre, Funder: Addenbrooke’s Charitable Trust, Funder: National Institute for Health Research (NIHR), Funder: Mark Foundation For Cancer Research, Funder: Cambridge Commonwealth, European and International Trust, Funder: Cancer Research UK, Funder: Cambridge Clinical Trials Unit, Funder: Cancer Research UK Cambridge Centre, Funder: Engineering and Physical Sciences Research Council Cancer Imaging Centre in Cambridge and Manchester, Funder: Cambridge Experimental Cancer Medicine Centre, PURPOSE: To detect early response to sunitinib treatment in metastatic clear cell renal cancer (mRCC) using multiparametric MRI. METHOD: Participants with mRCC undergoing pre-surgical sunitinib therapy in the prospective NeoSun clinical trial (EudraCtNo: 2005-004502-82) were imaged before starting treatment, and after 12 days of sunitinib therapy using morphological MRI sequences, advanced diffusion-weighted imaging, measurements of R2* (related to hypoxia) and dynamic contrast-enhanced imaging. Following nephrectomy, participants continued treatment and were followed-up with contrast-enhanced CT. Changes in imaging parameters before and after sunitinib were assessed with the non-parametric Wilcoxon signed-rank test and the log-rank test was used to assess effects on survival. RESULTS: 12 participants fulfilled the inclusion criteria. After 12 days, the solid and necrotic tumor volumes decreased by 28% and 17%, respectively (p = 0.04). However, tumor-volume reduction did not correlate with progression-free or overall survival (PFS/OS). Sunitinib therapy resulted in a reduction in median solid tumor diffusivity D from 1298x10-6 to 1200x10-6mm2/s (p = 0.03); a larger decrease was associated with a better RECIST response (p = 0.02) and longer PFS (p = 0.03) on the log-rank test. An increase in R2* from 19 to 28s-1 (p = 0.001) was observed, paralleled by a decrease in Ktrans from 0.415 to 0.305min-1 (p = 0.01) and a decrease in perfusion fraction from 0.34 to 0.19 (p
- Published
- 2022
- Full Text
- View/download PDF
23. Kinomic profiling to predict sunitinib response of patients with metastasized clear cell Renal Cell Carcinoma.
- Author
-
Oosterwijk-Wakka JC, Houkes L, van der Zanden LFM, Kiemeney LALM, Junker K, Warren AY, Eisen T, Jaehde U, Radu MT, Ruijtenbeek R, and Oosterwijk E
- Abstract
Introduction: Treatment with Sunitinib, a potent multitargeted receptor tyrosine kinase inhibitor (TKI) has increased the progression-free survival (PFS) and overall-survival (OS) of patients with metastasized renal cell carcinoma (mRCC). With modest OS improvement and variable response and toxicity predictive and/or prognostic biomarkers are needed to personalize patient management: Prediction of individual TKI therapy response and resistance will increase successful treatment outcome while reducing unnecessary drug use and expense. The aim of this study was to investigate whether kinase activity analysis can predict sunitinib response and/or toxicity using tissue samples obtained from primary clear cell RCC (ccRCC) from a cohort of clinically annotated patients with mRCC receiving sunitinib as first-line treatment., Materials and Methods: EuroTARGET partners collected ccRCC and matched normal kidney tissue samples immediately after surgery, snap-frozen and stored at -80°C until use. Phosphotyrosine-activity profiling was performed using PamChip® peptide microarrays (144 peptides derived from known phosphorylation sites in Protein Tyrosine Kinase substrates) of lysed tissue samples (5 µg protein input) of 163 mRCC patients. Evolve software Was used to analyze kinome profiles and Bionavigator was used for unsupervised and supervised clustering. The kinexus kinase predictor (www.phosphonet.ca) was used to analyze the peptide lists within the clusters., Results: Kinome data was available from 94 patients who received sunitinib as 1st-line treatment and had complete follow-up of their clinical data (PFS, OS and toxicity) for at least 6 months. Matched normal tissue was available from 14 mRCC patients. Supervised clustering of basal kinome activity could correctly classify mRCC patients with PFS >9 months versus PFS<9 months with an accuracy of 61 %. Unsupervised hierarchical clustering revealed 3 major clusters related to immune signaling, VEGF pathway, and immune signaling/cell adhesion. Basal kinase activity levels of patients with short PFS were substantially higher compared to patients who experienced extended PFS., Discussion/conclusion: Based on kinase levels ccRCC tumors can be subdivided into 3 clusters which may reflect the aggressiveness of these tumors. The accuracy of response prediction of 61 % based on basal kinase levels is too low to justify implementation. STK assays may help to predict sunitinib toxicity and guide clinical management. Additionally, it is possible that mRCC patients with an immune kinase signature are better checkpoint inhibitor candidates, but this needs to be studied., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: L. Houkes and R Ruijtenbeek are employed by PamGene International B.V., 5211 HH 's-Hertogenbosch, The Netherlands. The other authors declare that they have no competing interests., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
24. Hyperpolarized 13 C-Pyruvate Metabolism as a Surrogate for Tumor Grade and Poor Outcome in Renal Cell Carcinoma-A Proof of Principle Study.
- Author
-
Ursprung S, Woitek R, McLean MA, Priest AN, Crispin-Ortuzar M, Brodie CR, Gill AB, Gehrung M, Beer L, Riddick ACP, Field-Rayner J, Grist JT, Deen SS, Riemer F, Kaggie JD, Zaccagna F, Duarte JAG, Locke MJ, Frary A, Aho TF, Armitage JN, Casey R, Mendichovszky IA, Welsh SJ, Barrett T, Graves MJ, Eisen T, Mitchell TJ, Warren AY, Brindle KM, Sala E, Stewart GD, and Gallagher FA
- Abstract
Differentiating aggressive clear cell renal cell carcinoma (ccRCC) from indolent lesions is challenging using conventional imaging. This work prospectively compared the metabolic imaging phenotype of renal tumors using carbon-13 MRI following injection of hyperpolarized [1-
13 C]pyruvate (HP-13 C-MRI) and validated these findings with histopathology. Nine patients with treatment-naïve renal tumors (6 ccRCCs, 1 liposarcoma, 1 pheochromocytoma, 1 oncocytoma) underwent pre-operative HP-13 C-MRI and conventional proton (1 H) MRI. Multi-regional tissue samples were collected using patient-specific 3D-printed tumor molds for spatial registration between imaging and molecular analysis. The apparent exchange rate constant ( kPL ) between13 C-pyruvate and13 C-lactate was calculated. Immunohistochemistry for the pyruvate transporter (MCT1) from 44 multi-regional samples, as well as associations between MCT1 expression and outcome in the TCGA-KIRC dataset, were investigated. Increasing kPL in ccRCC was correlated with increasing overall tumor grade (ρ = 0.92, p = 0.009) and MCT1 expression (r = 0.89, p = 0.016), with similar results acquired from the multi-regional analysis. Conventional1 H-MRI parameters did not discriminate tumor grades. The correlation between MCT1 and ccRCC grade was confirmed within a TCGA dataset ( p < 0.001), where MCT1 expression was a predictor of overall and disease-free survival. In conclusion, metabolic imaging using HP-13 C-MRI differentiates tumor aggressiveness in ccRCC and correlates with the expression of MCT1, a predictor of survival. HP-13 C-MRI may non-invasively characterize metabolic phenotypes within renal cancer.- Published
- 2022
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.